Type 2 diabetes
Conditions
Interventions
None listed
Sponsors
Univ. Prof. Dr. Gert Mayer, Universitätsklinik für Innere Medizin IV (Nephrologie und Hypertensiologie)
Eligibility
Age
18 Years to 99 Years
Inclusion criteria
Inclusion criteria: 1. Patient age > 18 years 2. Incident or prevalent patients with type II diabetes mellitus 3. Patients who are willing to sign informed consent to provide blood and urine samples
Exclusion criteria
Exclusion criteria: 1. Patients with malignancy on current active treatment
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Renal outcomes are defined as * Progression from normoalbuminuria to microalbuminuria (including > 30% increase in albuminuria from baseline) * Progression from microalbuminuria to macroalbuminuria (including > 30% increase in albuminuria from baseline) * Progression to doubling of serum creatinine, end stage renal disease (ESRD) or death. Cut-off values indicating normoalbuminuria, microalbuminuria, and macroalbuminuria are defined as: 24 hour timed overnight first morning sample mg / 24 hour ug / min mg / g creatinin Normoalbuminuria 300 > 200 > 300 | — |
Secondary
| Measure | Time frame |
|---|---|
| Cardiovascular outcomes are defined as • cardiovascular death • non fatal myocardial infarction or non fatal stroke • hospitalization because of heart failure The diagnosis of cardiovascular events is made based on the treating physician*s judgement and checked by the adjudication endpoint committee. The adjudication endpoint committee consists of members located in each participating country. The national coordinator is responsible for annual random check of the quality of data entry. He/she is also responsible for correct patient follow up in case the treating physician changes. | — |
Countries
Netherlands
Outcome results
None listed